Clinical Study
Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study
Table 1
Patients’ demographics and the baseline International Prostate Symptom Score (IPSS).
| | Total | 75 mg group | 50 mg group | value | | () | () | () | (75 mg versus 50 mg) |
| | Age, mean (years) | 71.7 ± 9.4 | 72.1 ± 9.2 | 70.2 ± 10.5 | .559 | | Prostate volume, mean (mL) | 31.7 ± 24.8 | 34.6 ± 24.9 | 25.0 ± 24.8 | .403 | | Residual urine, mean (mL) | 24.0 ± 41.5 | 24.5 ± 43.3 | 22.4 ± 36.1 | .899 | | IPSS total | 17.2 ± 6.9 | 18.1 ± 7.2 | 14.2 ± 5.1 | .100 | | Storage score | 7.7 ± 3.5 | 7.8 ± 3.6 | 7.5 ± 3.3 | .780 | | Pollakisuria | 3.0 ± 1.6 | 3.1 ± 1.6 | 2.8 ± 1.8 | .602 | | Urgency | 1.9 ± 1.8 | 2.0 ± 1.9 | 1.5 ± 1.4 | .469 | | Nocturia | 2.8 ± 1.3 | 2.7 ± 1.3 | 3.1 ± 1.4 | .385 | | Voiding score | 7.2 ± 4.3 | 7.9 ± 4.3 | 5.0 ± 3.5 | .051 | | Intermittency | 2.2 ± 1.9 | 2.4 ± 2.0 | 1.7 ± 1.7 | .334 | | Slow stream | 3.2 ± 1.8 | 3.6 ± 1.6 | 2.1 ± 1.9 | .013 | | Straining | 1.7 ± 1.8 | 1.9 ± 1.9 | 1.2 ± 1.3 | .242 | | Postmicturition score* | 2.3 ± 1.8 | 2.5 ± 1.9 | 1.7 ± 1.6 | .233 | | QOL score | 4.8 ± 1.0 | 4.9 ± 1.0 | 4.6 ± 1.1 | .442 |
|
|
Score: mean ± standard deviation (SD); postmicturition score*, domain for feeling of incomplete emptying.
|
